PubMed Health⌕ Search

PubMed · 10460729

Locomotor forces on a swimming fish: three-dimensional vortex wake dynamics quantified using digital particle image velocimetry.

Abstract

Quantifying the locomotor forces experienced by swimming fishes represents a significant challenge because direct measurements of force applied to the aquatic medium are not feasible. However, using the technique of digital particle image velocimetry (DPIV), it is possible to quantify the effect of fish fins on water movement and hence to estimate momentum transfer from the animal to the fluid. We used DPIV to visualize water flow in the wake of the pectoral fins of bluegill sunfish (Lepomis macrochirus) swimming at speeds of 0.5-1.5 L s(-)(1), where L is total body length. Velocity fields quantified in three perpendicular planes in the wake of the fins allowed three-dimensional reconstruction of downstream vortex structures. At low swimming speed (0.5 L s(-)(1)), vorticity is shed by each fin during the downstroke and stroke reversal to generate discrete, roughly symmetrical, vortex rings of near-uniform circulation with a central jet of high-velocity flow. At and above the maximum sustainable labriform swimming speed of 1.0 L s(-)(1), additional vorticity appears on the upstroke, indicating the production of linked pairs of rings by each fin. Fluid velocity measured in the vicinity of the fin indicates that substantial spanwise flow during the downstroke may occur as vortex rings are formed. The forces exerted by the fins on the water in three dimensions were calculated from vortex ring orientation and momentum. Mean wake-derived thrust (11.1 mN) and lift (3.2 mN) forces produced by both fins per stride at 0.5 L s(-)(1) were found to match closely empirically determined counter-forces of body drag and weight. Medially directed reaction forces were unexpectedly large, averaging 125 % of the thrust force for each fin. Such large inward forces and a deep body that isolates left- and right-side vortex rings are predicted to aid maneuverability. The observed force balance indicates that DPIV can be used to measure accurately large-scale vorticity in the wake of swimming fishes and is therefore a valuable means of studying unsteady flows produced by animals moving through fluids.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

EG Drucker, GV Lauder. 1999. Locomotor forces on a swimming fish: three-dimensional vortex wake dynamics quantified using digital particle image velocimetry.. https://doi.org/10.1242/jeb.202.18.2393

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗